European Pharmaceutical Review
APRIL 30, 2024
If approved, fruquintinib could provide a new oral, chemotherapy-free option as the first and only selective inhibitor of all three vascular endothelial growth factor receptors (VEGFR) receptors approved in the EU for this disease, according to Takeda. This covers paediatric plaque psoriasis, psoriatic arthritis and Crohn’s disease.
European Pharmaceutical Review
JANUARY 30, 2024
Ryzneuta (efbemalenograstim alfa) received a positive opinion from the CHMP as a medicine to reduce the duration of neutropenia and the incidence of febrile neutropenia due to chemotherapy. Additionally, a positive opinion for Niapelf (paliperidone), a generic medicine for schizophrenia was adopted in the meeting.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
OCTOBER 6, 2022
The latter brought in acute myeloid leukaemia (AML) and cholangiocarcinoma therapy Tibsovo (ivosidenib), which was approved as a first-line therapy for AML last year in combination with Bristol-Myers Squibb’s chemotherapy Vidaza (azacitidine), dramatically expanding the eligible patient population for the drug.
European Pharmaceutical Review
APRIL 3, 2023
The committee recommended granting a paediatric-use marketing authorisation (PUMA) for Pedmarqsi (sodium thiosulfate) for preventing ototoxicity induced by cisplatin chemotherapy. Ototoxicity is the development of hearing or balance problems due to a medicine. Cisplatin is a chemotherapy used to treat several types of cancer.
European Pharmaceutical Review
DECEMBER 19, 2022
The group adopted a positive opinion for Tremelimumab AstraZeneca (tremelimumab), to treat metastatic non-small cell lung cancer (NSCLC) in combination with Imfinzi (durvalumab) and platinum-based chemotherapy. This rare genetic disorder causes muscle weakness and is often fatal.
Quality Matters
MAY 22, 2023
Identifying upstream supply chain vulnerabilities can help mitigate or prevent drug shortages After Laura Bray’s daughter was diagnosed with cancer and began chemotherapy treatment, she faced three separate shortages of the life-saving drugs she needed, all within nine months. kristine.gates… Mon, 05/22/2023 - 10:48 Supply Chain
Quality Matters
OCTOBER 24, 2023
Some hospitals have reported rationing doses in response to these shortages, and the American Society of Clinical Oncologists (ASCO) has issued new clinical guidance for treating patients with gastrointestinal (GI) cancers, which are commonly treated with carboplatin and cisplatin, two chemotherapy agents currently in shortage nationwide.
Expert insights. Personalized for you.
76 
Let's personalize your content